IDH

Semarchy Acquires Stambia Enhancing its Data Hub with Improved, Built-in Data Integration

Retrieved on: 
Monday, September 27, 2021
Cloud, Software as a service, Adoption, Software, CTO, Azure, Google Cloud Platform, Agility, Solution, GCP, News, AWS, Microsoft, Data management, IDH, CEO, Acquisition, General manager, Organization, XDM, Amazon Web Services, XDI, Microsoft Azure, Video game console

This acquisition will extend the Semarchy xDM Data Hub platform with comprehensive data integration capabilities, allowing the company to accelerate its innovation within data management and enhance its support of data fabric architecture.

Key Points: 
  • This acquisition will extend the Semarchy xDM Data Hub platform with comprehensive data integration capabilities, allowing the company to accelerate its innovation within data management and enhance its support of data fabric architecture.
  • "Since its inception, the Semarchy vision has been to build a single, full-featured, and integrated data hub product, but with agility and a strong focus on business value and outcomes.
  • Going forward, the Stambia product will be sold under the name xDM Data Integration (xDI) and will also become an integral component of the Intelligent Data Hub (IDH) platform, to deliver agile and flexible integration capabilities for any type of data integration, data hub or data management project.
  • Semarchy is the creator of the Intelligent Data Hub which empowers business users to become data champions.

Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

Retrieved on: 
Wednesday, September 15, 2021
ACT, U.S. Securities and Exchange Commission, Bone marrow, Degenerative disease, Security (finance), Venetoclax, DCR, Adoptive cell transfer, Antibody, FDA, AWE, AML, BMT, ARCS, Patient, Acute myeloid leukemia, Company, Cure, Clinical trial, IDH, Toxic epidermal necrolysis, CD45, Annual report, Leukemia, Salvage therapy, Form 10-Q, Refractory, Lymphatic system, Partnership, CD19, Relapse, Radiation, Population, ARC, Fred Hutchinson Cancer Research Center, SEC, FLT3, Pharmaceutical industry, Vaccine

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131. The SIERRA trial is a 150-patient, randomized and controlled study conducted at 24 leading bone marrow transplant centers in the United States and Canada. SIERRA is the only randomized Phase 3 trial to offer bone marrow transplant (BMT) to patients with active, relapsed or refractory acute myeloid leukemia (AML) age 55 and above, which is the only curative treatment option for this patient population.  

Key Points: 
  • The SIERRA trial is the only randomized Phase 3 trial to offer BMT to this patient population.
  • The SIERRA trial was conducted at 24 sites in the United States and Canada.
  • The SIERRA trial was conducted at 24 preeminent transplant centers in the U.S. and Canada.
  • Additional information on Iomab-B and the Phase 3 SIERRA clinical trial can be found at www.sierratrial.com .

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma

Retrieved on: 
Wednesday, August 25, 2021
Cancer, PFS, Priority review, IDH1, Progression-free survival, Food, Cholangiocarcinoma, IDH, Shanda, Tablet, Mutation, Review, Achievement, Adult, Enzyme, Patient, Caregiver, CEO, FDA, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

The FDA approval of this indication is supported by data from the ClarIDHy study, the first and only randomized Phase 3 trial for previously treatedIDH1-mutated cholangiocarcinoma.

Key Points: 
  • The FDA approval of this indication is supported by data from the ClarIDHy study, the first and only randomized Phase 3 trial for previously treatedIDH1-mutated cholangiocarcinoma.
  • The recommended TIBSOVO dosage for previously treated IDH1-mutated cholangiocarcinoma is 500 mg orally once daily with or without food until disease progression or unacceptable toxicity.
  • "This approval brings new hope to the cholangiocarcinoma community and we are excited that this much-needed new therapeutic option is being made available to patients."
  • Servier Pharmaceuticals is introducing ServierONE Patient Support Services, a program that offers one-on-one support to help patients who are prescribed TIBSOVO or other Servier products navigate their cancer journey.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Study 2020 with Sales Forecast to 2030

Retrieved on: 
Wednesday, March 11, 2020
Enzymes, Isocitrate dehydrogenase (NADP+) kinase, Isocitrate dehydrogenase, IDH

Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2020 provides comprehensive insights on the therapeutic development for this mechanism of action.

Key Points: 
  • Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2020 provides comprehensive insights on the therapeutic development for this mechanism of action.
  • The report provides the understanding of the unmet needs, market drivers and barriers of the Isocitrate Dehydrogenase inhibitors market.
  • Detailed profiles of therapeutic candidates in nonclinical stage, early-stage, mid-stage and late-stage of development for Isocitrate Dehydrogenase inhibitors (IDH inhibitors).
  • The report has also covered the worldwide market of Isocitrate Dehydrogenase inhibitors (IDH inhibitors), information of marketed therapies, their historical and forecasted sales till 2030.

Oncology Isocitrate Dehydrogenase Inhibitors Markets, 2022

Retrieved on: 
Wednesday, April 24, 2019
Enzymes, Medicine, Clinical medicine, Biomarkers, Oncology, Isocitrate dehydrogenase, IDH

DUBLIN, April 24, 2019 /PRNewswire/ -- The "Oncology Markets for Isocitrate Dehydrogenase Inhibitors Technology, Therapeutics, Markets, Strategies and Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 24, 2019 /PRNewswire/ -- The "Oncology Markets for Isocitrate Dehydrogenase Inhibitors Technology, Therapeutics, Markets, Strategies and Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • Predictive biomarkers for oncology are necessary to accurately identify patients who will benefit from anticancer treatment.
  • What is the size of the market for IDH inhibitors today, who are the market share leaders, and what will the market be in 2022?
  • What are the significant economic, technology, and regulatory factors affecting the market for biomarker-based oncology therapeutics?

Oncology Markets for Isocitrate Dehydrogenase Inhibitors Report 2019 - Technology, Therapeutics, Markets, Strategies and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 17, 2019
Health, Oncology, Enzymes, Medicine, Clinical medicine, Biomarkers, Oncology, Isocitrate dehydrogenase, IDH

The "Oncology Markets for Isocitrate Dehydrogenase Inhibitors Technology, Therapeutics, Markets, Strategies and Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oncology Markets for Isocitrate Dehydrogenase Inhibitors Technology, Therapeutics, Markets, Strategies and Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • Predictive biomarkers for oncology are necessary to accurately identify patients who will benefit from anticancer treatment.
  • What is the size of the market for IDH inhibitors today, who are the market share leaders, and what will the market be in 2022?
  • What are the significant economic, technology, and regulatory factors affecting the market for biomarker-based oncology therapeutics?

MFX External Party Integration Service Announces The Launch Of A New SaaS Based Offering

Retrieved on: 
Thursday, June 21, 2018
Economy, Software, As a service, Software as a service, Software distribution, Software industry, Bridgewater, Insurance, IDH, Computing

BRIDGEWATER, N.J., June 21, 2018 /PRNewswire/ --MFX Services, a specialized global vertical system integrator and digital transformation leader for the P&C Insurance industry, announces the launch of a new SaaS based offering, "External Party Integration ("EPI")", driven by MFX's proven industry specific "Insurance Data Hub ("IDH").

Key Points: 
  • BRIDGEWATER, N.J., June 21, 2018 /PRNewswire/ --MFX Services, a specialized global vertical system integrator and digital transformation leader for the P&C Insurance industry, announces the launch of a new SaaS based offering, "External Party Integration ("EPI")", driven by MFX's proven industry specific "Insurance Data Hub ("IDH").
  • At the core of the offering is MFX's IDH, rich with over 15 years of insurance specific intelligence designed to optimize the quality of data and streamline the integration process.
  • With our EPI Service, we have bridged the data-chasm between External Party and Carrier allowing each to focus on their respective businesses."
  • Headquartered in Bridgewater, NJ, MFX has additional locations and datacenters in Virginia, Texas, Toronto and multiple development centers in India.

TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten® for the Treatment of Intradialytic Hypotension

Retrieved on: 
Tuesday, May 29, 2018
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Nephrology, Hemodialysis, Dialysis, IDH, Home hemodialysis, Intradialytic parenteral nutrition

"Intradialytic hypotension is a serious and frequent complication of hemodialysis; associated with increased morbidity and mortality in hemodialysis patients.

Key Points: 
  • "Intradialytic hypotension is a serious and frequent complication of hemodialysis; associated with increased morbidity and mortality in hemodialysis patients.
  • The Fast Track designation will enable us to work closely with the FDA to accelerate our efforts to potentially provide an impactful solution for these vulnerable patients," said Shlomo Sadoun, CEO of TrioxBio.
  • The Company plans to initiate Phase II clinical trials for Raviten in the United States later this year.
  • Intradialytic hypotension (IDH) is a serious and frequent complication of hemodialysis therapy, associated with increased morbidity and mortality in end-stage renal disease patients receiving maintenance hemodialysis.